The authors aimed to identify possible factors associated with mortality among multidrug resistant and extremely drug resistant tuberculosis cases in Lithuania. The theme is very relevant and data that may help in the management of these cases are of relevance for an international readership. The text is in general well written and clear, but it may need a thorough review to correct some terms (e. g. use of isoniasid instead of isoniazid). The authors properly identify the main limitations of the study and study conclusions provide support for treatment decision-making. The inclusion of strain genotyping in the analysis of factors predicting survival, even though limited, is original and provides a basis for insight about Beijing strain biological behavior.
Minor comments/questions: 1) In the introduction, the authors refer to the prevalence of MDR TB and XDR TB in Lithuania, and state that drug resistance in these settings is associated with high rates of default and low rates of treatment success, which are not observed among drug susceptible cases. The last sentence of this paragraph states that "Lithuania has one of the highest mortality rates in the WHO European Region (6.3/100 000)", from the context it can be assumed that these data refer to mortality due to MDR TB; is this correct? 2) Time of treatment until diagnosis of M/XDR TB, hospitalization and hypoalbuminemia have been associated to poor outcome and shorter survival in other settings; it would be interesting to include these variables in the analyses if available and to see how they might impact on the results. 3) Is rural living associated with more limited access to health care and/or treatment in Lithuania? 4) Is treatment efficiency with second line drugs influenced by strain type (Beijing versus nonBeijing)? 5) If survival time is plotted against drug regimens shown here to influence on survival using a scatter plot, it could provide an easily readable basis for the assertion made by the authors that the "combination of ethionamide/prothionamide with ofloxacin appeared to be at least as effective as a FQ with an injectable", in the Discussion section.
REVIEWER
Thorsten Thye, Bernhard Nocht Institute for Tropical Medicine REVIEW RETURNED 12/09/2011
THE STUDY
The abtract includes to many figures. It is unreadable.
RESULTS & CONCLUSIONS None

REPORTING & ETHICS None
GENERAL COMMENTS
1. The main weakness of the study as stated by the authors themselves is the lack of information with regards to the HIV infection status (76.1% missings for XDRTB and 83.1% for MDRTB). Since adjusting for confounders implicates that only those individuals are included in such analyses where information from all confounders is available. This means that only a subset of individuals is analysed in the adjusted Cox regression due to the missing HIV tests (17 XDR / 293 MDR). Therefore, it should clearly be stated how many people where analysed in the adjusted and not-adjusted regression analyses and this information should be included in the manuscript and in table 2. It should also be mentioned clearer and more specific how lacking HIV information may lead to biased study results, as HIV positivity may influence the outcome of other confounders.
2. The abstract is almost unreadable due to the many figures included. This should be changed to ensure more legibility.
3. Data from the national TB register should be used to include prevalence of MDR and XDR tuberculosis in the years throughout the surveillance period.
VERSION 1 -AUTHOR RESPONSE
Reviewer: Thorsten Thye, University of Hamburg The abstract includes too many figures. It is unreadable.
1. The main weakness of the study as stated by the authors themselves is the lack of information with regards to the HIV infection status (76.1% missings for XDRTB and 83.1% for MDRTB). Since adjusting for confounders implicates that only those individuals are included in such analyses where information from all confounders is available. This means that only a subset of individuals is analysed in the adjusted Cox regression due to the missing HIV tests (17 XDR / 293 MDR). Therefore, it should clearly be stated how many people where analysed in the adjusted and notadjusted regression analyses and this information should be included in the manuscript and in table 2. It should also be mentioned clearer and more specific how lacking HIV information may lead to biased study results, as HIV positivity may influence the outcome of other confounders.
The analysis includes patients in three categories of HIV status: positive, negative, or not tested. HIV status would only have been regarded as missing if it was unknown whether a test had been done. We have made this clearer in the Methods and in the relevant table entries. The number of people with complete data (98%) is given at the beginning of the results. We have added to the text the number of people whose TB strains were genotyped, who were included in the subsidiary analysis of strain family -note this corresponds to the total number in Table 1 with known strain. 2. The abstract is almost unreadable due to the many figures included. This should be changed to ensure more legibility.
Agree; we have removed the p-values from the text of the abstract and simplified the presentation of 95%CIs. We felt it was important to include quantitative results in the Abstract, however, if the editor believes that stating the main risk factors without providing estimates of their effects is sufficient, we will delete the latter.
Agree, additional figure (now Figure 1) is added to reflect the changes in the MDR and XDR incidence and prevalence levels.
Reviewer: Theolis Costa Barbosa Bessa, Centro de Pesquisas Gonçalo Moniz -Fiocruz/BA, Brasil A STROBE checklist has been provided and all items it contains have been properly addressed in the text.
The authors aimed to identify possible factors associated with mortality among multidrug resistant and extremely drug resistant tuberculosis cases in Lithuania. The theme is very relevant and data that may help in the management of these cases are of relevance for an international readership. The text is in general well written and clear, but it may need a thorough review to correct some terms (e. g. use of isoniasid instead of isoniazid).
Agree; now "isoniazid " is used throughout the text
The authors properly identify the main limitations of the study and study conclusions provide support for treatment decision-making. The inclusion of strain genotyping in the analysis of factors predicting survival, even though limited, is original and provides a basis for insight about Beijing strain biological behavior.
Minor comments/questions: 1) In the introduction, the authors refer to the prevalence of MDR TB and XDR TB in Lithuania, and state that drug resistance in these settings is associated with high rates of default and low rates of treatment success, which are not observed among drug susceptible cases. The last sentence of this paragraph states that "Lithuania has one of the highest mortality rates in the WHO European Region (6.3/100 000)", from the context it can be assumed that these data refer to mortality due to MDR TB; is this correct?
The data refer to the overall mortality among TB patients in Lithuania in data supplied to the European Center for Disease Control (ECDC); the ECDC report from 2009 indicated that the cause of this high mortality was not known, i.e. whether it was associated with MDRTB or advanced/untreated drug sensitive TB. By conducting our analysis we were aiming to answer this question more precisely, i.e. to identify whether the high mortality is indeed attributable to MDR/XDRTB. To make the statement more explicit, we have added the mortality rates among new and re-treatment cases and modified it to: "Mortality rates among newly diagnosed cultureconfirmed cases is high (10.3%); it is one of the highest in re-treatment TB cases in the WHO European Region (22.3%); the explanation for the high mortality remains unknown."
2) Time of treatment until diagnosis of M/XDR TB, hospitalization and hypoalbuminemia have been associated to poor outcome and shorter survival in other settings; it would be interesting to include these variables in the analyses if available and to see how they might impact on the results.
Agree in principle; the data on hypoalbuminemia is unfortunately not available for the analysed dataset. All smear-positive and almost all culture-positive patients are hospitalised for the intensive phase of treatment in Lithuania. All MDRTB patients are hospitalised. Normally hospitalisation takes place on the second or the third day after a patient's presentation to a TB clinic; therefore we did not include this variable into analysis. The data on duration of symptoms until the diagnosis and consequent hospitalisation was not available. We did not include the time of treatment until diagnosis of MDR/XDRTB into the analysis as this period was variable across the years but relatively similar within the years depending on the coming availability of modern DST methods. For example, in 2002-05 only solid-based DST methods were available, from 2006 -liquid media systems became available and in the last 2 years -LPSs. This determined the average treatment length prior to initiation of the second-line therapy.
3) Is rural living associated with more limited access to health care and/or treatment in Lithuania?
The country has a well-developed TB clinical structure that provides access to treatment to all patients from both urban and rural settings. However, the fact that rural living is associated with poorer survival (even adjusting for the education level and alcohol consumption that is assumingly higher among rural residents) highlights possible difficulties in accessing the care, e.g., the necessity of coming to a clinic and costs associated with it. To emphasize this issue, we have added the following sentence (page 11, second paragraph from the bottom): "The independent impact of rural living on survival may indicate possible obstacles in accessing TB treatment facilities in the country despite a well-established system of TB care; the issue warrants further investigation by local health agencies ." 4) Is treatment efficiency with second line drugs influenced by strain type (Beijing versus nonBeijing)?
We did not analyse factors associated with successful or unsuccessful treatment outcomes within the scope of this analysis. We have assessed the impact of infection with a Beijing family strain on survival as well as the impact of SLD treatment on survival; however, the relation between a SLD regimen and a strain type was not analysed. 5) If survival time is plotted against drug regimens shown here to influence on survival using a scatter plot, it could provide an easily readable basis for the assertion made by the authors that the "combination of ethionamide/prothionamide with ofloxacin appeared to be at least as effective as a FQ with an injectable", in the Discussion section. This is an interesting comment but because this is survival data, the appropriate plot would be a series of survival curves rather than a scatter-plot. We wanted to limit the overall number of Tables and Figures, and we do not agree that a series of 12 overlapping survival curves would be easier to read than a table quantifying the relative effects. Thus we felt that the table (which also quantifies the imprecision in the estimates) was the best way to present drug regimen differences. 
REPORTING & ETHICS
None
GENERAL COMMENTS
The authors have addressed all comments satisfactorily.
